Genmab A/S (GNMSF)
PNK · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Peers in Healthcare
Genmab A/S has no peer companies in this window.
Recent press releases
April 2026
GENMAB A/S — 6-K Filing
# 🧾 What This Document Is This is a standard regulatory filing, called a 6-K, from the biotech company Genmab. Its sole purpose is to publicly disclose stock transactions made by its top executives. Think of it as a required transparency report so investors know what the company's leaders are doin
GENMAB A/S — 6-K Filing
# 🧾 What This Document Is This is a **6-K filing**, which is a report international companies like Genmab (based in Denmark) submit to the U.S. SEC to announce major events. This specific event is a **"Major Shareholder Announcement."** It's a formal notification required by Danish law when an inve
March 2026
GENMAB A/S — 6-K Filing
# 🧾 What This Document Is This is a **6-K form**, which is a current report filed with the SEC by foreign companies (like Danish Genmab) to share important events with U.S. investors. This specific filing is a "Major Shareholder Announcement." It's like a mandatory public notification saying, "Hey,
SEC filings
All filings →Insider trades
All insider trades →Genmab A/S has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at Genmab A/S
All people →No officers or directors have been indexed for Genmab A/S.
Quarterly financials
Full financials →No quarterly financials have been ingested for Genmab A/S.